- Hanks GF, Pajak T, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz E, Lawton C, Rosenthal S, Sandler H, and Shipley W. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: RTOG Protocol 92-02. Journ Clin Oncol 21(21) 3972-3978, 2003.
- Pollack A, Grignon D, Heydon K, Hammond E, Lawton C, et al. Prostate cancer DNA plody and response to salvage hormone therapy after radiotherapy with or without short term total androgen blockade: An analysis of RTOG 86-10 Jour Clin Oncol 21(7):1238-1248, 2003.
- Roach M, Lu JD, Lawton C, Hsu I-C, Machtay M, Seider MJ et al. A phase III trial comparing whole-pelvic (WP) versus prostate only (PO) radiotherapy and neoadjuvant versus adjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 94-13. Jour Clinc Onc 21(10) 1904-1911, 2003.
- Lawton, C: Hormones and Radiation Therapy in Locally Advanced Adenocarcinoma of the Prostate. Seminars in Rad Onc 13:2, 141-151, April 2003.
- Lawton, C., Winter, K., Grignon, D. and Pilepich, M.: Androgen Suppression plus Radiation versus Radiation Alone for Patients with D1 (pN+) Adenocarcinoma of the Prostate (Updated Results Based on a National Prospective Randomized Trial, RTOG 85-31). (Accepted 11/03 J Clin Oncol.)
- Shipley, W., Lu, J., Pilepich, M., Heydon, K., Roach, M., Wolkov, H., Sause,
W., Rubin, P., Lawton, C. and Machtay, M.: The Effect of a Short Course of
Neoadjuvant Hormone Treatment on the Response to Subsequent Androgen
Suppression in Prostate Cancer Patients who Relapse Following Radiation
Therapy: A Secondary Analysis of the Randomized Protocol RTOG 86-10. Int J
Radiat Onco Biol Phys, 54:5, 1302-1310, 2002.
- Lawton C, Winter K, Murray K, Machtay M, et al. Routine long-term androgen suppression following standard radiotherapy improves disease-free survival in men with unfavorable-prognosis prostate cancer compared with relapse-initiated therapy. Evidenced-based Oncology 2002 0, 1-2.
- Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, et al: Age dramatically impacts on the quality-adjusted time without symptoms of toxicity (Q-twist) in locally advanced non-small cell lung cancer (LA-NSCLC) A RTOG analysis (Submitted to Jour Clinical Onc 10/01)
- Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, et al. Analysis of risk factors for the development of GVHD after T-cell depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility and method of T-cell depletion. Biology of Blood and Bone Marrow Transplantation 7(11), 620-630, 2001.
- Burt RK, Cohen BA, Lobeck LJ, Karlin, K, Russell E, Spero K, Lawton CA, et al: Immune suppressive therapy with autologous stem cell rescue for progressive Multiple Sclerosis: A pilot safety study. (Submitted Jour Neurology 5/2001)
- Pilepich MV, Winter K, Fu KK, Russell AH, Sause W, Rubin P, Lawton C, Machtay M, and Grignon d: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Rad Onc Bio Phys 50:5, 1243-1252, 2001.
- Juckett M, Cohen E, Keever-Taylor C, Lawton C, Moulder J, and Klein J. Loss of Renal Function Following BMT: An Analysis of Angiotensin Converting Enzyme D/I Polymorphism and Other Clinical Risk Factors. Bone Marrow Transplantation 27:4, 451-456, 2001.
- Lawton C, Winter K, Murray K, Machay M, Mesic M, Hangs G, Coughlin C, and Pilepich M. Updated results of the phase II RTOG trial 85-31 evaluating the potential benefit of androgen suppression deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Rad Onc Bio Phys 49:4, 937-946, 2001.
- Horwitz E, Winter K, Hanks G, Lawton C, Russel A, and Machay M. Subset Analysis of RTOG 85-31 and 86-10 indicate an advantage for long-term versus short-term adjuvant hormones for patients with locally advanced non-metastatic Gleason score 7-10 prostate cancer treated with radiation therapy. Int J Rad Onc Bio Phys 49:4, 947-956, 2001.
- Roach M.,Lu J., Pilepich M., Asbell S., Mohiudden M., Terry R., Grignon D., Lawton C., Shipley W., and Cox J. Predicting Long Term Survival, and the Need for Hormonal Therapy: An Analysis of RTOG Prostate Cancer Trials 85-06 through 86-10. Int J Radiation Oncology Biol Phys 47(3):617-627, 2000.
- Scott, C., Roach, M., Lawton, C.,, Gallagher, M..Doggett, S., Hanks, G., Coughlin, C: Q-Twist Analysis of Men Treated for Prostate Cancer with Radiotherapy with or without Neoadjuvant Combined Androgen Blockade: Based on Radiation Oncology Group 86-10. l Quality of Life Research 8(7): #48, 568, 1999.
- Movsas B, Scott C, Sause M, Byhardt R, Ritsuko K, Cox J, Johnson D, Lawton C, Dar A., Wasserman T, Roach M, Lee J, and Andras E. The Benefit of Treatment Intensification is Age and Histology-dependent in Patients with Locally Advanced Non-small Cell Lung Cancer (NSCLC): A Quality-Adjusted Survival Analysis of Radiation Therapy Oncology Group (RTOG) Chemo-Radiation Studies. Int J Rad Onc Bio Phys 45:5, 1143-1149, 1999.
- Lawton, C., Grignon, D., Newhouse, J., Schellhammer, P., and Kuban D. RSNA Oncodiagnosis Panel: 1997, RadioGraphics. 19:1, 185-203,1999.
- Watkins Bruner, D., Scott, C., McGowan, D., Lawton, C., Hanks, G., Prestidge, B., Han, S., Gore, E., and Asbell, S. The RTOG Modified Sexual Adjustment Questionnaire: Psychometric Testing in the Prostate Cancer Population. Int Jour of Rad Onc Bio Phys 42(1) #156, 202,1998.
- Byhardt R, Scott C, Sause W, Emami B, Komaki R, Fisher B, Lee J, and Lawton C. Response, Toxicity, Failure Patterns and Survival in Five Radiation Therapy Oncology Group (RTOG) Protocols of Sequential and/or Concurrent Chemotherapy and Radiotherapy for Locally Advanced Non-Small Carcinoma of the Lung. Int Jour of Rad Onc Bio Phys 42(3) 469-478, 1998.
- Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski W, Hanson G, Horowitz M, Lawton C, Margolis J, Peitrygga D, and Vesole D. T- Cell depleted allogeneic bone marrow transplantation for high risk non-Hodgkin lymphoma: Clinical and molecular follow up. Bone Marrow Transplantation, 21:893-899, 1998.
-
Lawton C, Winter K, Grignon D, and Pilepich M: Androgen Suppression plus Radiation versus Radiation Alone for Patients with D1 (pN+) Adenocarcinoma of the Prostate (Updated Results Based on a National Prospective Randomized Trial, RTOG 85-31). J Clin Oncol 23:4, 800-807, 2005.
-
Li XA, Wang JZ, Jursinic P, Lawton C, and Wang D.: Dosimetric advantages of IMRT simultaneous integrated boost for high risk prostate cancer. Int J Rad Onc BiolPhys 61:4, 1251-1257, 2005.
-
Pilepich M, Winter K, Lawton C, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma long term results of phase III RTOG 85- 31. Int J Rad Onc Biol Phys, 61:5, 1285-1290, 2005.
-
Shipley WU, DeSilvio M, Pilepich M, Roach M III, Mesic JB, Sause WT, Rubin P, and Lawton C: Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Rad Onc Biol Phys 64:4, pp 1162-1167, 2006.
-
Abdel-Wahab, B Berkey, A Krishan, T O'Brien, E Hammond, M Roach III, C Lawton, M Pilepich, A Markoe, A Pollack: Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Journal of Clinical Oncology 29:1, 14-20, 2006.
-
Lee WR, DeSilvio M, Lawton C, Gillin M, et al: A Phase II Study of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate: Preliminary Results of RTOG P-0019. Int J Rad Onc Bio & Phys 64:3, 804-809, 2006.
-
Lawton CA, DeSilvio M, Lee WR, et al: Results of a phase II trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate. (RTOG 98-05) (Accepted 8/06 Int J Rad Onc Biol & Phys)